EUVIMEDEUVIMED entdecken
Crossref

Sodium Zirconium Cyclosilicate for the Acute Management of Hyperkalemia in the Emergency Department

Nicole Gasparovic iD, Amanda Buckallew iD, Sara Richter iD

Annals of Pharmacotherapy · 2025

DOI: 10.1177/10600280251336245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Nicole Gasparovic und 2 weiteren Autor:innen. Beteiligte Einrichtung: Missouri Baptist Medical Center, St. Louis, MO, USA. Hauptthemen laut MEDLINE: Hyperkalemia, Silicates. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited evidence exists examining the use of potassium binders for the acute management of hyperkalemia.

Objective

The objective of the study is to evaluate the use of sodium zirconium cyclosilicate (SZC) for the acute management of hyperkalemia.

Methods

This retrospective cohort study evaluated patients presenting to the emergency department with an initial potassium ≥5.6 mEq/L and treated with the institutional hyperkalemia order set.

Results

Overall, 189 patients were included. There was no significant difference in serum potassium change from baseline to first potassium within 6 hours between the SZC and non-SZC groups (−1.096 ± 0.71 vs −1.067 mEq/L ± 0.81, P = 0.798), respectively. No significant difference was seen between the SZC and non-SZC groups for time from initial hyperkalemia to order set medication administration (1.9 ± 1 vs 2.5 ± 2.9 hours, P = 0.63), mean hospital length of stay (5.5 ± 4.5 vs 6.6 days ± 6.9, P = 0.197), or potassium level at first recheck (5.17 ± 0.68 vs 5.34 mEq/L ± 0.76, P = 0.108). Time from the first medication administration to potassium recheck differed by about 1 hour between groups (4.1 ± 3.1 vs 5.1 hours ± 3.2, P = 0.035), and patients in the SZC group were less likely to have a potassium >6 mEq/L at the first recheck (10.1% vs 21%, P = 0.047). Conclusion and Relevance: The optimal use of SZC in the acute management remains uncertain based on results from this study with no difference in potassium levels at first recheck.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperkalemiaSilicatesHumansRetrospective StudiesMaleFemaleEmergency Service, HospitalMiddle AgedAgedPotassiumCohort StudiesLength of Stay

Stichwörter der Autor:innen

Lokelmaemergency departmenthyperkalemiapotassium binderssodium zirconium cyclosilicate

Substanzen

Silicatessodium zirconium cyclosilicatePotassium

Autor:innen und Institutionen

  • Missouri Baptist Medical Center, St. Louis, MO, USA.
  • St. Louis College of Pharmacy, University of Health Sciences and Pharmacy in St. Louis, St. Louis, MO, USA.

ORCID-Profile: Nicole Gasparovic, Amanda Buckallew, Sara Richter

Zitieren

APA

Gasparovic, N., Buckallew, A., & Richter, S. (2025). Sodium Zirconium Cyclosilicate for the Acute Management of Hyperkalemia in the Emergency Department. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251336245

Vancouver

Gasparovic N, Buckallew A, Richter S. Sodium Zirconium Cyclosilicate for the Acute Management of Hyperkalemia in the Emergency Department. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280251336245

BibTeX
@article{Gasparovic2025,
  author = {Gasparovic, Nicole and Buckallew, Amanda and Richter, Sara},
  title = {Sodium Zirconium Cyclosilicate for the Acute Management of Hyperkalemia in the Emergency Department},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  doi = {10.1177/10600280251336245}
}
Kostenlos starten →